Aspire Biopharma Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:ASBP)

Shares of Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) are scheduled to reverse split on Monday, May 11th. The 1-30 reverse split was announced on Thursday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 8th.

Aspire Biopharma Stock Performance

Aspire Biopharma stock traded down $0.03 during trading on Thursday, hitting $0.16. The company’s stock had a trading volume of 160,902,912 shares, compared to its average volume of 9,635,640. The stock’s fifty day moving average is $0.87 and its 200 day moving average is $3.58. Aspire Biopharma has a 1-year low of $0.12 and a 1-year high of $35.01. The stock has a market capitalization of $778,720.00, a price-to-earnings ratio of -0.01 and a beta of 0.21.

Aspire Biopharma (NASDAQ:ASBP) last released its earnings results on Monday, March 30th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.00 million during the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ASBP shares. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of Aspire Biopharma

A number of institutional investors have recently modified their holdings of ASBP. Jane Street Group LLC raised its holdings in Aspire Biopharma by 2,252.1% in the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd grew its stake in Aspire Biopharma by 853.2% during the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in Aspire Biopharma during the third quarter worth approximately $28,000. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.